Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 78

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 78
---
 common stock listed
above were deemed exempt from registration under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that
the issuance of securities did not involve a public offering.

| ● | On the effective date of our initial public offering registration statement, we issued 1,158 shares of our common stock to Mountjoy Trust as a result of the conversion of the Convertible Promissory Note we issued to Mountjoy Trust on May 19, 2022 (the “Mountjoy Note”). |

| ● | From October 2024 to January 2025, we issued an aggregate of 579,711 shares of common stock upon the exercise of pre-funded warrants issued to investors in the September 2025 private placement. |

The issuance of the capital stock listed above
was deemed exempt from registration under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance
of securities were made to an accredited investor and did not involve a public offering. The recipient of such securities represented
its intention to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution
thereof.

(b) Warrants.

On September 4, 2024, we issued 579,711 pre-funded
warrants, 579,711 Series A Warrants and 579,711 Series B Warrants to investors in a private offering. The Pre-Funded Warrants are exercisable
immediately upon issuance and expire when exercised in full at an exercise price of $0.005 per share. The Series A Warrants and Series
B Warrants have an exercise price of $6.90 per share and will be exercisable beginning on the effective date of stockholder approval of
the issuance of the shares of Common Stock (the “Stockholder Approval”) upon exercise of the Common Warrants. The Series A
Warrants will expire five years from Stockholder Approval and the Series B Warrants will expire eighteen (18) months from Stockholder
Approval. H.C. Wainwright & Col, LLC acted as the exclusive placement agent in connection with the Private Placement. In connection
with the Private Placement, we issued to H.C. Wainwright & Co., LLC the Placement Agent Warrants to purchase 43,479 shares of Common.
The Placement Agent Warrants have an exercise price equal to $8.625 per share and are exercisable beginning on the effective date of the
Stock